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THE IMPACT OF IoT TECHNOLOGY ON 
PHARMACEUTICAL GREEN SUPPLY CHAIN MANAGEMENT 
Rabia Celik 
 
This research aims to explore the current state and role of Internet of Things (IoT) technology in Green 
Supply Chain Management (GSCM) practices through examination of the pharmaceutical industry.  
Internet of Things technology, Green Supply Chain Management practices and the pharmaceutical 
industry were the main topics investigated from existing works, in order to identify possible 
correlations, existing technology solutions and challenges.    
The research approach was exploratory in nature, the data was collected through interviews with three 
pharmaceutical companies and one public health care distributor centre. The interviews produced 
qualitative and quantitative data, which were analysed with a pragmatic philosophy. The dual nature of 
findings created a detailed and comprehensive view of IoT benefits and challenges when the technology 
is implemented within the organisation, and when is used to support GSCM practices. In details, the 
findings were analysed to summarize major drivers for IoT adoption, challenges and future possibilities. 
On the other side, this research investigated how IoT enables and supports GSCM practices.  
The combination of primary and secondary data served to uncover the positive relationship between 
IoT solutions, sustainability and business value, with significant benefits discussed throughout the 
findings. This research confirmed that IoT technology allow business growth and indirectly enables 
sustainable practices.  The overall positive impact of IoT in pharmaceutical GSCM practices discovered 
in this research, confirmed that exists a strong relationship between sustainability and business value, 
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CHAPTER ONE: INTRODUCTION 
1.1 OVERVIEW 
This research will investigate how the adoption of Internet of Things (IoT) technology improves green 
supply chain management practices in the pharmaceutical companies and what are the potential 
difficulties through an exploratory method. The following section includes research purpose, 
significance of study, research objective and structure of study. 
1.2 RESEARCH PURPOSE 
The purpose of the research is to understand how IoT adoption improves green supply chain 
management practices within pharmaceuticals. 
Over the last two decades we experimented a fast development and integration of new technologies in 
organizations, with the purpose to improve the performance and increase the value of the company. 
Information Communication and Technology (ICT) has demonstrated to be an effective instrument for 
the productivity, flexibility, and competitiveness of the organization. Furthermore, ICT develops an 
effective inter organizational networks, it is enough to think about sharing information between 
suppliers, producers and buyers. In particular, IoT is gaining relevance along the market and scholars, 
due to the ability to connect stand-alone object (e.g. devices, vehicles, machines, containers) through 
the internet, that when integrated with software has the potential to collect, analyse and control data 
over the internet (Gubbi et al., 2013). 
IoT technology is a progression of the classical ICT Information communication technology (e.g., 
email, phone, bar code, ERP). It differs from ICT applications for ubiquity, intelligence and autonomy 
(Kahlert et al., 2017), adding the potentiality to capture information, exchange it in real-time and 
automatically processed (Ferreira et al., 2010). On the other side, recently a large number of consumers 
and businesses are always more interested to sustainable and environmentally friendly products when 
making a purchase decision. Furthermore, global consciousness on the importance of an economic, 
environmental and social sustainable market, leads governments and legislations to require compliance 
by manufacturers, retailers, brand managers, traders, and distributors. 
The application of environmental management principles to the entire set of activities across the whole 
customer order cycle, including design, procurement, manufacturing and assembly, packaging, 
logistics, and distribution (Handfield et al., 1997; Islam et al., 2017) are having strong impact and giving 
an important value to pharmaceutical companies.  
A strong interest along researchers and businesses is having the implementation of IoT technology 
along the supply chain, in order to obtain performance improvement and a sustainable business 
advantage (Cui, 2018; Rocha et al., 2017).  
The research gives insight into IoT technology implementation and challenges in pharmaceutical 




1.3 SIGNIFICANCE OF THE STUDY 
The implementation of a green supply chain is becoming always more crucial and unavoidable for 
organizations, due to government regulations, environmental concerns, and market thrust (customer 
decision).  
A better insight of a specific technology, in this case IoT is a key factor for the development of a 
successful supply chain. This research can help pharmaceutical organizations to evaluate and decide if 
proceed in a certain direction. Furthermore, study the impact of IoT challenges in the GSCM, it is 
helpful to determine where an organization should put more effort, in order to obtain the maximal 
beneficial effect from the use of IoT in the GSCM. 
GSCM and IoT are still young research fields. The interaction of these two different topics in 
pharmaceutical industry, may enable innovation. support future researches and real applications.  
1.4 RESEARCH OBJECTIVE 
To fully understand IoT’s potentiality and the possible role into the pharmaceutical GSCM, a literature 
review of IoT capability, GSCM practices and pharmaceutical industry is necessary. Once those 
arguments are analysed, a deeper understanding of IoT integration in SCM and pharmaceutical GSCM 
was possible.  
As previously mentioned, the research aims to understand how IoT adoption enables and improves 
pharmaceutical green supply chain management practices through a survey base and interview research 
method. The following hypothesis will be verified: 
Hypothesis: H1: IoT capability has a positive effect on supplier, customer and internal integration.  
H2: IoT capability has a positive impact on GSCM in the Pharmaceutical industry 
H3: Adoption of IoT in GSCM generates disadvantages.  
1.5 STRUCTURE OF STUDY 
This dissertation separated into 6 chapters. Each chapter contributes to the research objective and the 
process for exploring the proposition. 
The first chapter represents to introduce the purpose of the research, the significance of the study, the 
research objective and how the research will be structured.  
The second chapter provides a complete literature of IoT technology, Green supply chain management 
practices and pharmaceutical industry. The literature review is the key to fully understand and identify 
possible correlations, existing technology solutions and IoT challenges.   The literature is broken down 






The third chapter describes the methodology and research approach. This chapter aims to clarify the 
methodology and strategy that was used to collect the primary data, which is both qualitative and 
quantitative. For the purpose of this research, a pragmatic approach was taken through the survey and 
interviews. 
Chapters four and five present the findings from the collection of the primary data. It also contains a 
discussion section which contrasts and compares the findings with the conducted literature review. The 
findings and discussion chapter are designed to explore the results of the research. 
The final chapter highlights implications, limitations and recommendations for future research. It also 
includes both conclusions and reflections. The following chapter is a literature review that was explored 















CHAPTER TWO: LITERATURE REVIEW 
2.1 OVERVIEW 
To fully understand the impact of IoT on the GSCM in the Pharmaceutical Industry the literature review 
critically explores the three main topics involved in this research. First of all, IoT technology has been 
presented from a technical point of view, in order to fully appreciate the potential and the advantages 
that could bring to the SCM and GSCM. An investigation of IoT technology disadvantages has been 
also undertaken, to understand which problems can arise from the implementation of this technology. 
Is important to highlight that the research aim is also to empirically verify the truthful and grade of the 
disadvantages. 
A deeper investigation has been done on the integration of customer, supplier and internal information, 
using IoT enabled supply chain, due to the fact that the supply chain integration is a key factor for a 
successful GSCM (De Vass et al., 2018; Yu et al., 2017). Subsequently, GSCM practices have been 
analysed to create an effective survey for the research. 
Finally, the literature review critically explores the pharmaceutical industry and the impact that it has 
on the environmental, the challenges in implementing a sustainable and green supply chain, and how 
IoT technology can be implemented to support GSCM in the pharmaceutical industry.   
2.2 INTERNET OF THINGS 
2.2.1 THE ORIGIN OF INTERNET 
The technological evolution began with early research on ARPANET and packet switching which is a 
commercial network that developed by National Physical Laboratory (NPL) a way of avoiding 
congestion in busy networks by cutting up data at one end and putting back together at the other (Leiner 
et al., 2009). 
The internet today is widespread information infrastructure, there is no a single founder of the internet. 
There are many researches and scientists behind the evolution of the internet.  
Leiner et al. described the internet briefly: 
“The internet is at once a world-wide broadcasting capability, a mechanism for information 
dissemination, and a medium for collaboration and interaction between individuals and their computers 
without regard for geographic location” (Leiner et al., 2009). 
According to ARPANET, that one of the founders of the first network, in the 1960’s first network 
experiment aim was not communication, the aim was optimizing process usage, or time sharing, in 
particular sharing the power of the computer at once.  
CYCLADES is a packet-switching network that was invented in early 1970’s as an alternative to 





By the end of 1969 there were few computers connected to the ARPANET and kept grow in 1970’s 
and there was no single global internet, then Transmission Control Protocol and Internet Protocol 
(TCP/IP) developed by Robert Kahn and Vinton Cerf. TCP/IP is a communication model that set 
standards for how data could be transmitted between multiple networks and adopted by ARPANET. In 
early 1980s Domain Name System (DNS) was invented by Paul Mockapetris, the DNS permitted a 
scalable distributed mechanism for resolving hierarchical host names (e.g. www.acm.org) into an 
Internet address (Leiner et al., 2009). The online world then took on a more recognizable form in 1990, 
when computer scientist Tim Berners-Lee invented the World Wide Web. 
2.2.2 WHAT IS INTERNET OF THINGS 
The Internet of things (IoT) is defined by Gubbi et all as ‘Interconnection of sensing and actuating 
devices providing the ability to share information across platforms through a unified framework, 
developing a common operating picture for enabling innovative applications. This is achieved by 
seamless ubiquitous sensing, data analytics and information representation with Cloud computing as 
the unifying framework’ (Gubbi et al., 2013). In other word IoT is modern wireless technologies (e.g. 
Radio-Frequency Identification, tags, sensors, actuators, mobile phones, etc.)  that are able to interact 
with each other and cooperate for the common goal (Atzori et al., 2010). 
IoT technology enables real time collection and analysis of huge amounts of data making it available 
through the Internet. The monitored data can be analysed in real time with a proper network and server 
infrastructure. An appropriate set of real-time alarms can be configured to advise potential safety threats 
in a timely manner. Not only proper alarm can be configured, but also effective action can be taken 
automatically from the IoT device, if an actuator is used. This is the real advantage of IoT technology, 
it differ from Information and Communication Technology (ICT) applications for ubiquity, intelligence 
and autonomy (Patel et al., 2016). In general sense of IoT applications is extended internet services and 
devices that provides business and society better information process beyond computers or smart 
phones. 
The impact of IoT technology enhanced every-day life users both working and domestic fields over the 
past decade. For instance, consumer connected devices include smart TV, smart speaker, toys and smart 
wearable technology such as smart watches, glasses etc.  
An idiomatic example is in the cold supply chain. A temperature-sensing IoT device will ensure that 
highly perishable product remains within safe temperature ranges (Chandra and Lee, 2014), so to protect 
the consumer. If the temperature is out of the ranges a temperature control can be applied from the IoT 
device in autonomous way. 
The Internet of Things consists of four main technologies summarized as follow:  
1. Radio Frequency Identification (RFID) (Lee and Lee, 2015) allows data gathering via radio waves, 
a reader and a tag. The tag is used to store data and the reader to capture it, the interaction is all 




2. Passive RFID are not battery powered, and they are commonly used in the retail and supply chain 
management (Gubbi et al., 2013).  
3. Active RFID instead rely on their own battery and can engage communication with the reader. 
General applications are monitor temperature, pressure, chemicals, and other conditions, they are 
mainly used in manufacturing, hospital laboratories, and remote sensing (Lee and Lee, 2015) 
4. Wireless Sensor Network (WSN) consists in a distributed autonomous network of sensor devices 
used in remote sensing applications; they differ from RFID due to the capability to share the sensor 
data to a centralized system for analytics. RFID have a limited processing capability and storage when 
compared to WSN (Gubbi et al., 2013).    
5. Cloud computing is a concept for access a wide pool of resources (servers, sensor, applications) over 
the internet. IoT devices generate an enormous amount of data directly available via internet, this can 
enable the creation of a virtual Infrastructure as a Service IaaS or a Software as a Service SaaS (Lee 
and Lee, 2015) 
6. IoT applications enable interaction between human and technology through a customization of the 
software to tailor any business needs (Lee and Lee, 2015). IoT application allows efficient exploiting 
of data gather by IoT devices and it can be used to integrate and elaborate various data along the 
supply chain.  
2.2.3 IOT ADOPTION IN SUPPLY CHAIN 
IoT technology if properly implemented allows the full virtualization and integration of the supply chain 
management; this is the main advantage of assuming such technology in the company.  All the actors 
involved in the supply chain (suppliers, customers and internal) are now able to monitor, control, plan 
and optimize business processes (Ferreira, et al., 2010) remotely and in real-time through the Internet, 
based on virtual objects instead of observation on-site (Verdouw, et al., 2013). Furthermore, 
virtualization permits artificial intelligence to be exploited in the processes.  
 
Figure 1: Virtualization of the supply chain from IoT perspective 




One of the strongest in sight industry by governments and customers, due to the necessary of high-
quality product has always been the pharmaceutical sector. Not authenticity or damage of pharmacies 
causes high losses to the government and companies but also seriously healthy issue to the customer 
life. Internet of things makes possible improvement in monitoring for drug supply chain, and also 
update drugs information in real time (Yan and Huang, 2009). The pharmaceutical factory can use 
IoT in several phases: manufacturing, warehousing and cold chain distribution. 
 
 
Figure 2: IoT applied to pharmaceutical supply chain 
(Saboo et al., 2017) 
 
Equipment needs to be continually maintained and calibrated to assure the safety and efficacy of drug 
products, sensor network is the best solution to monitor in real time the performance of the 
manufacturing process and target manufacturing error. 
Real-time tracking and 3-D view of warehouse operations with detailed, contextually relevant data at 
their fingertips allows to: 
• Monitor and track sensitive and expensive medicines in controlled zones. 
• Optimize the warehouse space. 
• Track and reduce inventory of finished goods. 
• Keep track of the situation and aware issues that require human intervention. 
Finally, the distribution monitoring and remote control in this sector is becoming vital, pharmaceuticals 
manufacturers are commencing always more biologic products, which are highly sensitive to storage 
conditions. IoT devices can be positioned with the drugs during the shipment, the temperature sensor 
continually records temperatures and environmental condition, which can be recorded and checked by 
the control centre.  
IoT devices can be also used to implement environmentally friendly procedures and controls, for 
example optimizing the warehouse space and track and reduce inventory will results in a reduce of 




Nowadays, case studies and publications of IoT in Supply chain management, focus only on specific 
sensors and network to be implemented in particular case. To obtain the best result IoT needs to be 
properly embedded into the supply chain, for this reason, it becomes essential define and develop an 
information system architecture (Verdouw et al., 2016) that considers the full chain from suppliers to 
consumer. 
Another sector where the IoT integration results vital is the food industry; high quality standard imposed 
by the government and customers can be monitored from the farm to the table. 
The information in the food supply chain follows a distributed architecture. For example, Electronic 
Product Code Information Services (EPCIS) is the used standard to realize distributed traceability 
systems between several suppliers in the food industry. 
 
Figure 3Virtualization in the food supply chain management 
(Verdouw, et al., 2013) 
 
2.2.4 SUPPLY CHAIN INTEGRATION 
Supply chain integration is a collaborative management strategy between suppliers, customers and 
intra-organization. An intra & inter organizational cooperation create effective and efficient flows of 
products, information and provide the maximum value to the end customer at the lowest cost and the 
greatest speed (De Vass, et al., 2018) . 
Supplier and customer integration refers to strategic common management, information sharing and in 
general collaboration between suppliers and customers  (Wu, 2013; Yu et al., 2017). Instead internal 
integration refers to the breakdown cross-function barriers within the organization speed (De Vass, et 
al., 2018). In order to obtain successful supply chain integration a system that joins all the information 
retrieved along every step of the supply chain is necessary. Supply chain integration is the last step of 




One software useful for this purpose is FIspace (Verdouw, et al., 2014), it is a cloud-based platform for 
business collaboration, which is based on a common set of Internet technology. The following Figure 
(4) shows all the step of the food supply chain and the correspondent virtual layers created via IoT 
devices. These virtual layers are joined with FIspace, that become an intermediary platform between 
them and allow handling information, problem notification and decision-making. 
 
Figure 4: Information systems architecture for the food supply chain 
(Verdouw, et al., 2014) 
 
2.2.5 CHALLANENGES OF IOT ADOPTION 
The advantages of IoT are undeniable, and widely documented, but almost no research focus on the 
negative impact that IoT can have on the SCM. We can assume that IoT adoption brings the same 
disadvantage for SCM. 
Privacy issue and security concerns are the main disadvantage of IoT applied to the SCM (Weber, 
2010), (Weber, 2015). 
Some of the data that are collected appear to be not important but they revel indirectly production 
process and company policies, these data are highly valuable and requires an adequate protection, for 
this reason know the security issues affecting those technology (U.Farooq et al., 2015) is a must for the 
success of the SCM. 
Skill gap in control and management to make profitable this new technology is another major issue, 
As reported by Shah, (2017) “Almost a third of executives at large global enterprises believe that the 
IoT faces a major skills gap, and that this is preventing businesses from being able to exploit new 
capabilities”. 
Management of huge amount of data gathered by IoT devices is another aspect that if underestimated, 
can lead to an inefficient use of IoT technology. For this reason, the use of management software to 




Furthermore, integration of IoT technology in an existing infrastructure can create additional 
challenges, such as compatibility issue. 
Malfunctions is another issue; the intrinsic autonomy of this technology make possible automatic 
action such as place an order for goods or discard materials. When the decision-making process is 
automatic, a malicious malfunction could cause huge problems, and difficult to identify. 
2.3 GREEN SUPPLY CHAIN MANAGEMENT 
2.3.1 THE CONCEPT 
The GSCM researches and practices have been increasing over the last decades due to customer 
requirements, environmental legislations and regulation. In addition, Sustainable Development Goals 
(SDGs) have a significant impact on the adoption of green practices. SDGs are a number of goals that 
take into consideration economic, environmental, social issues and set by United Nations (Bebbington 
and Unerman, 2017). 
Srivastava (2007) as cited by Micheli et al. (2012) the concept of GSCM is “integrating environmental 
thinking into supply chain management, including product design, material sourcing and selection, 
manufacturing processes, delivery of the final product to the consumers as well as end-of-life 
management of the product after its useful life”. 
The purpose of GSCM is to satisfy customers demand for green products and services produced by 
green processes. Such as eliminating hazardous chemical and solid waste, reducing energy consumption 
and CO2 emission from entire supply chain (Green et al., 2012). Moreover, different GSCM studies 
show that successful practices and initiatives can be done in various are such as reverse logistics, 
product recovery and reuse of used products, green design, green procurement, and collaboration with 
suppliers and customers (Islam et al., 2017). 
2.3.2 GREEN SUPPLY CHAIN MANAGEMENT PRACTICES 
Reverse Logistic 
The reverse logistic a useful practice for green supply chain management and it aims to reduce negative 
environmental impact of organizations, maximize the value of unused items, conserve resources and 
minimize cost (Skinner, et al., 2010). Reverse logistic is defined as monitoring the physical of products, 
components and materials flowing from users/owners to re-users (Glenn Richey et al., 2005). The goods 
are moving back from customers to manufactures or distributors rather than traditional logistic. GSCM 
focuses on both environmental issues and economic concerns. Therefore, reverse logistic can play an 






According to Tseng et al., (2013) most studies have broadly considered “green design” idea for end-of-
life product to recover valuable components. Nevertheless, a green design is an approach to building 
goods and services with environmental awareness (Tseng et al., 2013).  
For instance, reducing carbon footprint, resource conservation, cleaner production, waste management, 
pollution prevention etc. (Zhu and He, 2017) 
Green Procurement 
Green procurement is a process of acquiring goods and services that take into consideration 
environmental, social and economic impact (Trivedi and Singh, 2016). Green procurement practices 
have a significant impact on green supply chain management. 
Collaboration with Suppliers and Customers (Supply chain integration) 
Building environmental collaboration between organization and customers, organization and supplier 
reduce cost and negative environmental impact of supply chain (Pagell and Wu, 2009). Therefore, it 
has an incontrovertible role in GSCM. 
Green Manufacturing 
‘Green manufacturing considers environmental impacts throughout the product lifecycle including the 
sale of used, unsold, or returned products in secondary markets’(Islam et al., 2017). Green 
manufacturing process involves reducing use of sources, using green energy, and reusing wastes etc. 
Green manufacturing can lead to lower raw material cost for organizations. 
2.4 PHARMACEUTICAL INDUSTRY 
2.4.1 OVERVIEW 
The pharmaceutical industry has a vital role in modern economy, developing medications and vaccines 
to reduce the spreading of disease, to cure diseases and improve the people’s life (Nead, 2017). 
Pharmaceutical Industry first objective is to meet complex and always increasing healthcare demands 
of populations. In order to do so, companies in this industry are responsible of researching, developing 
manufacturing and distributing drugs for human or veterinary needs (ITA, 2016). The research and 
creation of innovative drugs have a clear and massive impact on global health, economic grow and 
prosperity of population, by improving life and eliminating deadly disease. Pharmaceutical industry is 
complex and wide, drugs are produced in various form such as pills, tablets, capsules, vials, ointments, 
powders, solutions and suspensions. Furthermore, there are several pharmaceutical product sectors; 
drugs can be innovative or generic products, chemically derived or biologically derived products, 
prescription-based or over-the-counter products. Although pharma industry presents a wide range of 
products across several sectors, the core remains the same across: R&D, manufacturing, distribution 





The origin of pharmaceutical industry lies back to the middle age when pharmacies were providing 
traditional remedies based on centuries of folk knowledge (Walsh, 2010). This is far from our 
understanding of the industry today, pharmacology science developed during the 19th century with 
Oswald Schmiedeberg generally recognised as the founder of modern pharmacology (Hester and 
Harrison, 2015) and two main companies Merck, Eli Lily and Roche that had developed and supplied 
natural products such as morphine in large-scale production of drugs for the first time.  
Meanwhile, new companies as ICI, Pfizer and Bayer started to establish research labs and develop new 
medical products and applications. During the beginning of the 20th century and second war world 
several inventions were made as penicillin, insulin, aspirin which allowed the pharmaceutical industry 
to develop and flourish. Finally, the implementation of the healthcare system in several countries and 
the intervention of the government created a stable market. Between the 1950 and 1990 an endless 
stream of improved products have released, making this period the golden age of the pharmaceutical 
industry. Since then the industry has faced a series of new challenges and problems, ranging from 
sustainability to expiring licence.  
Nowadays pharmaceutical market is one of the most competitive and complex, due to a large number 
of laws and regulations for patenting, testing, safety, sustainability that affect the growth rates of the 
market. Furthermore, high development costs for creating new medicines can be a barrier for small 
companies (The Business Research Company, 2018). However, the Pharmaceutical global market is 
expected to grow at an annual rate of 4.9% to $1.3 trillion by 2020 (ITA, 2016). 
2.4.2 ENVIRONMENTAL IMPACT 
Till the late 1990s pharmaceutical industry was not considered to have massive negative environmental 
impact (Daughton, 2016), environmental awareness and company responsibility is a relative new topic 
and the only environmental concern was related to manufacturing facilities. This view has changed 
since pharmaceutical residues has been found in surface waters in 1994, pharmaceuticals can enter the 
environment in three ways from the wrong disposal of expired drugs, via excretion from patients and 
from manufacturing sites (Hester and Harrison, 2015). Drugs once used by human can follow several 
paths, from dispersion in open water to the land field affecting animals with clear consequences for 
humans and the environment. Pharmaceutical compounds enter the environment at every stage of the 
supply chain, but major pollution is during the manufacturing phase. Releasing antibiotics in the 
environment can promote the development of antibiotic-resistant pathogens (Nawrat, 2019). 
Pharmaceuticals in the environment is not the only challenge in this sector, big and global companies  
like Merck, Pfizer, Abbvie, Sanofi, Amgen, J&J and Roche, Eli Lilly, P&G, Abbott, GSK, Teva, 
Novartis and Astrazeneca are responsible to emit massive quotative of GHG emission. Pharmaceutical 
sector is far from being a green sector. In fact, the sector's emission intensity in 2015 was 48.55 Mt-
CO2e/$M, which is about 55% higher than that of the Automotive sector of 31.4 Mt-CO2e/$M for that 




The study showed also that the whole sector would need to reduce emissions by 58.6%, from 2015 
levels, by 2025 in order to comply with emission targets established in the Paris Agreement.  
Following figures shows carbon emission intensity of pharmaceutical and automotive industries. 
 
Figure 5: Emission intensities for 15 pharmaceutical companies in 2015, shown with the emission 
intensity of the pharmaceutical sector in 2015, along with projected levels in 2020 and 2025 
(Belkhir and Elmeligi, 2019) 
 
Figure 6: Emission intensities for 10 auto makers in 2015, shown with the emission intensity of the 




(Jackson and Belkhir, 2018) 
 
From a general point of view, the environmental impacts can be classified as direct (those on which the 
company can actually operate) and indirect (which relay on consumers). 
Irresponsible disposal of unused medicines and release of pharmaceuticals in the environment by 3rd 
party waste companies and users have indirect negative impacts on the environment and pharma 
companies have little influence on those issues.  
Instead, companies have a huge responsibility on direct impacts like pollution and carbon emission 
when transporting medicines, or energy and material consumption when producing medicines. 
 
Figure 7: Environmental impact of pharmaceuticals 
(Sanofi, 2018) 
 
All those concerns demonstrate that need of higher attention to the supply chain in order to mitigate 
every negative impact of the pharmaceutical industry on the environment. The Figure (7) above 





2.4.3 GREEN SUPPLY CHAIN IN PHARMACEUTICALS 
GSCM practices aim the integration of environmental management thinking in the whole supply chain 
process including source of raw materials, product design, manufacturing, delivery of the product and 
end of life product (Khan, 2018).The concept of GSCM is becoming a popular trend in the Pharma 
Industry due to pressure of government’s regulations, pollution and environmental concerns of the 
consumers.  
The pharmaceutical product leftovers carry an environmental risk to join manufacturing process. 
Researchers found some pharmaceutical leftovers like painkillers, antidepressants, antimicrobials etc. 
in drinking waters, ground waters and some animal tissue. 
The regulator agencies like EMA (European Medicine Agency) and FDA (Food and Drugs 
Administration) are requiring more complex business process and stricter reporting methods. The 
European Commission (EC) have issued a set of goals across Europe to achieve green and more 
sustainable business by 2030. Some multinationals leading pharmaceutical companies like Pfizer etc. 
have already shifted their traditional business strategy to sustainable business model (Bravo and 
Carvalho, 2013). 
The traditional pharmaceutical supply chain management has been very profitable in the market. Study 
cases show that adopting environmental thinking in the business operations has several positive impacts 
on the businesses, including better quality management, increased margin profit, competitive 
advantage, reputation and positive image, greater customer satisfaction (Porter and Kramer, 2019). 
The pharmaceutical supply chain involves primary manufacturers, secondary manufacturers, logistics 
service providers/wholesalers, healthcare providers and retail outlets (Ding, 2018).  
Green Network Design and Warehouse 
The pharmaceutical industry relies on air transportation other than sea and rail transportation for its 
speed, reliability and efficiency in delivering high-value, time-sensitive, temperature-controlled cargo.  
However, green warehouse and supply chain network design practices has crucial impact in order to 
improve more sustainable, green and environmentally friendly supply chain management activities 
(Dukkanci et al., 2019). Many pharma companies are redesigning their network and warehouse due to 
protect environment and increase efficiency supply chain model. Practices include relocation of 
chemistry plants and pharmaceutical plants, encouraging sea transportation rather than air 
transportation, developing railway transportation in the supply chain network, decreasing number of 
trucks on the road and using renewable energy vehicles in terms of green network design. For instance, 
Sanofi has started a new project in Paris using only Natural Gas Vehicles and in Saõ Paulo launched 
anti-flu campaign using only electric vehicles due to improve quality of green supply chain 
management. In other words, everything starts with energy in the supply chain process, like every 
business pharmaceutical companies reduce energy consumption along the supply chain including 





Pharmaceutical manufacturing may comprise environmentally dangerous chemicals and toxics 
(European Comission, 2017). The green manufacturing practice is referred to practicing 
environmentally friendly processing and production flow. Pharma manufacturing process can be 
divided into series of units depending on the goods produced. Green practices in production improve 
efficiency of processes.  
Green production process involves responsible and sustainable raw material sources, fermentation, 
shifting indigents, dry mixing, blending, coating, packaging, resource recovery and recycling, 
warehouse monitoring etc.  
Energy efficiency has a significant role in the green pharmaceutical manufacturing in order to achieve 
sustainable manufacturing process. Due to “green manufacturing” term using cleaner energy and 
decreasing energy consumption are significant way to address this goal. Renewable energy resources 
are main way to achieve energy efficiency during the manufacturing process. For instance, big 
companies like Roche, Merck, Sanofi, Bayer, Pfizer and Eli Lily etc. publishes every year annual 
reports. The reports include their sustainability practices and environmental impacts including energy 
consumption, carbon emission, water usage. In order to achieve green energy practices in 
manufacturing process companies reduce their usage of fossil fuels, cut energy consumption, and 
increase the proportion of sustainable energy like solar energy, wind powers, hydropower etc. 
According to Roche’s annual report, they include the implementation of innovative technologies and 
continuous upgrading of infrastructure to improve energy efficiency, usage of sustainable energy 
increased since 2015 by 6.3% and decreased total un-sustainable energy consumption by 7.7% 
meanwhile sales grew 7% (Roche, 2018). Another effective green manufacturing practice is reducing 
greenhouse carbon emission along manufacturing process.  
The Paris Agreement is an agreement that aims to tackle climate change and greenhouse gas emission, 
countries that signed, accepted and approved to decrease their greenhouse carbon emission 20% and 
increase 20% renewable energy in energy efficiency by 2025 (United Nations, 2015). For instance, 
Sanofi divides into three scopes greenhouse carbon emission by end 2025. Scope 1 & 2 determines 
industrial, R&D and tertiary sites, including the medical rep fleet. Scope 3 is GHG emissions are the 
other indirect emissions associated with other functions of the value chain including transportation, 
purchased goods and services, waste generation, etc. (Sanofi, 2019). According to company report 
carbon emission decreased by 22% since 2010 and 9% by 2018 using Planet Mobilization Program, 
Maalox case study and renewable energy sources. 
Waste Management 
Waste management takes important part in the green supply chain management, waste management 





Health waste divided into two category as communal waste and biomedical waste. Communal waste 
are solid wastes that are non-chemical (Jaseem et al., 2017) e.g. boxes, paper, food waste, plastic and 
glass bottles. Biomedical wastes are special waste that can be extremely hazardous for the environment 
e.g. cultures, tissues, needles, scalpels, knives, blades, expired or no longer needed medicines or 
pharmaceuticals, genotoxic waste, chemical waste, radioactive waste etc. (Pratyusha et al., 2012). 
However, pharmaceutical companies practice green waste management along with resource recovery, 
recycle and energy recovery.  
Furthermore, “ISO 14001 certification helps organizations to improve their existing environmental 
standard and waste reduction” (Faisal, 2015). As an illustration, Sanofi decreased hazardous waste by 
12% and non-hazardous waste by 9% compared to 2017 with “implementation of the new wastewater 
treatment plant enabling the increase of on-site treatment” (Sanofi, 2019), Pfizer reduced disposing 
waste by 15% compared to 2012 (Pfizer, 2018), GlaxoSmithKline decreased the waste by 7% that they 
produce since 2016 (GSK, 2018). 
“Pharmaceutical companies are using the Global Reporting Initiative as a way to implement and 
measure their level of sustainability” (Bravo and Carvalho, 2013).  
The findings of the report include transparency and environmental performance. The adoption of 
GSCM practices like generation of waste, increasing efficiency of materials and energy, innovating by 
new and environmentally friendly products and services improves pharmaceutical industry and increase 
businesses competitive edge amongst rivals. Linton et al. effectively explains that this type of approach 
leads to the increase business performance and profitability, sustaining their activities longer. 
2.4.4 IOT IN GREEN SUPPLY CHAIN PHARMACEUTICALS 
Only a few previous researches have investigated IoT practices in pharmaceutical green supply chain 
management. There are several common kind practices of IoT like RFID and WSN and cloud 
computing etc. that have been discussed earlier in literature. However, since pharmaceutical regulatory 
agencies persuade high pressure on industry in terms of concerning environment and sustainability 
practices companies improving the use of technology to address government regulations.  
According to Marathe and Awwad (2018) study,  IoT brings solutions to GSCM challenges faced by 
pharmaceutical companies, these challenges categorised as: real time visibility, collaboration issues, 
temperature control, warehouse management, regulatory compliance and data handling. 
Real time visibility 
In pharmaceutical GSCM practices visibility and traceability is very crucial. IoT technologies enable 
traceability in terms of GSCM practices, including waste reduction, energy consumption, greenhouse 
gas emission, transportation and reverse logistic. For instance, some drug shortages like oncological 
medicines pose a significant public health concern (Nonzee and Luu, 2019), “ theft and the counterfeit 
of drugs during the transit period is one of the major concerns for every pharma company” (Marathe 




The following figure illustrates real time 3-D view of IoT in the pharmaceutical supply chain integration 
within Enterprise Resource Planning (ERP) and Warehouse Management System (WMS). 
 
Figure 8: IoT in warehouse 
(Marathe and Awwad, 2018) 
 
Collaboration 
The importance of transparency and reporting in pharmaceutical GSCM initiatives, data sharing with 
suppliers and vendors might be big challenge for pharmaceutical companies. Furthermore, complex 
data flow can cause delays and trust problem with the partner organisations. Pharma businesses can 
take advantage of IoT to improve data management. For example, IBM ‘Smarter Supply Chain of 
Future’ study case enforces IoT technologies to improvement and smooth data flow with suppliers, 
vendors, third parties and business partners.  
Temperature control 
The cold chain has significant value in procurement and supply chain, due to temperature sensitive 
health care products like vaccines etc. IoT apply in cold chain through wireless sensors and batteries. 
According to (Saboo et al., 2017) 20% of temperature sensitive biologic pharmaceutical goods are 
wasted during transit. IoT helps to maintaining desired storage conditions of temperature and humidity 
sensitive. Regarding to (Archa et al., 2018) study, IoT implementation can reduce pharmaceutical 
product wastes and helps to ensure compliance  with regional and international target market norms and 





2.5 CONCEPTUAL FRAMEWORK 
The initial phase of the conceptual framework was derived from the literature review in the previous 
section (Section 2).  
Based on the researcher’s understanding of this topic from the literature review, the author proposed a 
conceptual framework as illustrated in Figure (9) for an adoption of IoT technology in the 
Pharmaceutical Supply Chain Management practices, most of all in green supply chain practices. 
The conceptual framework based on a resource-based view (RBV) theory, RBV suggests that a 
competitive advantage comes from possessing valuable and rare resources that competitors cannot 
easily acquire or reproduce, in this case IoT solutions.  
Therefore, the study proposes that IoT adoption has a positive effect on the supply chain integration, 
which is the main aspect to obtain a successful GSCM within pharmaceutical industry. Supply chain 
integration is not the only positive impact included in the conceptual framework; the positive impact of 
the remaining green practices is under study. There are no consistent literatures (secondary resources) 
on IoT impact on these GSCM practices implementations, opportunities and challenges. Furthermore, 
disadvantages of IoT technology are reported as a general topic, this study aims to gather a complete 
and comprehensive view of IoT adoption in the Pharmaceutical green supply chain. 
 
 
Figure 9: Conceptual Framework of the Study 
 
The dependent variables of the study listed as following: (1) the integration of IoT technology on supply 
chain, (2) the implementation and the impact of IoT on pharmaceutical supply chain, additionally (a) 




The independent variable of the study determined as the implementation of IoT technology within the 
company. Primary data collected from the literature review has shown that an academic study on IoT 
impact on the GSCM is poor and not focused on pharmaceutical industry, furthermore no case study 
has been found on this specific topic. 
The case study analysed and reported in the literature review were mainly theoretical, hypothetical or 
based on the general supply chain management, rather than focalize on the green supply chain 
management. Moreover, no study has been found that analyses the environmental impact of IoT use in 
the pharmaceutical industry. 
As a consequence, the conceptual framework of this study aims to link IoT technology and 
pharmaceutical green supply chain management with the help of primary data gathered from a range of 
Pharmaceutical companies and public healthcare centres.     
 
Hypothesis: H1: IoT capability has a positive effect on supplier, customer and internal integration.  
H2: IoT capability has a positive impact on GSCM in the Pharmaceutical industry 
H3: Adoption of IoT in GSCM generates disadvantages.  
 
Once defined the hypothesis to verify within this study, a research methodology has been selected to 
obtain the most clear and comprehensive data result.  
Due to the many independent variables and the many way IoT Technology can be implemented within 
the Pharmaceutical company under review, in deep interview has been adopted as a method to gather 
data.  Finally, a deductive approach has been followed to extrapolate meaningful findings to grade the 
impact and the challenges of the IoT technology in the GSCM. The findings are subsequently compared 





CHAPTER THREE: METHODOLOGY AND RESEARCH DESIGN 
3.1 OVERVIEW 
This chapter outlines the research philosophy, research strategy, data collection and analysis 
methodology to carry out the research, define findings and reach the conclusions.  
The objective of this research is to discover how IoT technology impacts pharmaceutical supply chain 
management in terms of green practices.  
Saunders et al. (2009) clearly defined research methodology ‘…techniques and procedures used to 
obtain and analyse data. This, therefore, includes questionnaires, observation and interviews as well as 
both quantitative (statistical) and qualitative (non- statistical) analysis techniques…’ and he used ‘The 
Research Onion’ to illustrate different levels of the research methodology process. The principal 
research levels are as follow: 
• Research philosophy 
• Research approach 
• Research strategy 
• Research choices (i.e. single, mixed or multiple methods) 
• Time horizons (i.e. cross-sectional or longitudinal) 
• Techniques and procedures (i.e. data collection methods and data analysis). 
(Saunders et al., 2009) 
3.2 RESEARCH PHILOSOPHY AND APPROACH 
This chapter explains the main philosophical framework that will guide this research. The research in 
subject involves two main topics: IoT technologic management, and the effect of IoT adoption in the 
pharmaceutical GSCM, those two topics will be evaluated using a pragmatic philosophy. 
A pragmatic philosophy gives the freedom to use any of the methods or techniques associated with 
qualitative or quantitative, in order to mitigate the limitations that every method can introduce (Saunders 
et al., 2009). On the other side, this freedom grade, introduces increased difficulty in the integration of 
data. The pragmatic philosophy assumption is the result of two different aspects of the research. 
First of all, the positive or negative impact of IoT adoption could be perceived in a different manner, 
depending by the organization and interviewed person, for this reason there is space for subjective 
interpretation (interpretivism). It is important to notice that a sample can be influenced by subjective 
interpretation, and the data can be subject of value bias. In order to decrease the effect of the bias a 
mixed method approach will be used.   
From another point of view, the impact of IoT adoption is something that can be quantified, using 
quantitative data (Linkert scale survey) (Boone, Jr. and Boone, 2012). Moreover, the research aims to 






Figure 10: The research onion 
(Saunders et al., 2009) 
 
Positivism relies on quantifiable observations in our case a survey with closed-ended questions. 
Furthermore, the results of this survey are based on human senses and objective situation. Moreover, in 
positivism studies “the researcher is independent from the study and there are no provisions for human 
interests within the study” (Crowther and Lancaster, 2012). 
A positivism philosophy usually adopts a deductive approach. A deductive approach is when hypothesis 
are developed, and the analysis of the data will support or not the hypothesis.  
In this research three hypotheses have been developed studying what others have done and what are the 
existing theories. Analysing the research data, we will discover if they support or not that hypothesis. 
This is a clear deductive approach. 
For all those reasons, a pragmatic philosophy is the most suitable for the intrinsic dual nature. 
Using a positivism philosophy, descriptive and quantitative data will be collected and analysed; instead, 
interpretivism philosophy will be used for qualitative in deep results. In this research, the quantitative 
data will be improved with a qualitative approach, in order to verify the hypothesis (deductive 
approach). The quantitative data will be collected via a closed ended survey (Likert scale), then a had 
doc interview will be performed based on the result of the survey and other secondary data, in order to 





3.3 RESEARCH STRATEGY 
The strategy used to collect the data was dedicated to verifying and confirm three hypotheses. Those 
three hypotheses define the impact that IoT technology can have on the GSCM more specific in 
pharmaceutical. The research has been designed as follow, not only to confirm if IoT technology has a 
positive impact on GSCM practices for organisations, but also to explore issues and problematics that 
can be introduced when using IoT within pharmaceutical supply chain. 
A mixed methods research involves collection, analysis and integration of qualitative and quantitative 
data. The study uses a simple mixed methodology, joining a quantitative survey with a qualitative post 
hoc interview, those qualitative questions have been created after analyse survey data, because their 
purpose it to clarify some reply and gain further qualitative insights. The interview is also required for 
investigate on disadvantage and negative impact of IoT technology within the organization.  
The survey is a Likert scale questionnaire, for nature is defined as positivism and quantitative research.  
The survey’s scope is not only verifying the hypothesis, but also gain information on the actual IoT 
technology implemented in the firm’s GSCM. 
A cross sectional time horizon is considered; the interviews will gather data from multiple samples, as 
many as the researcher will be able to gather, at one point in time, this will provide a statistical snapshot 
of a specific point in time. 
A mix of descriptive and exploratory is proposed as the most suitable approach for this research. It is 
explorative because there is no exhaustive research done previously in the field under study. Moreover, 
there is no existing study that explores and verifies the third hypothesis. 
It is in part descriptive, because the survey-based analysis will gather information on the use of IoT 
technology in the GSCM. 
3.4 COLLECTION PRIMARY DATA 
This section outlines the sources of the primary data collected, access and ethical issues related to the 
collection of data.  
3.4.1 SOURCE OF DATA 
As explained in previous section, this research exploits a mixed methods research as source of data, in 
the specific a Likert survey model and a post-created ad doc interview. 
Due to the nature of the data, the research is mainly based on primary data collection as survey, 
interview and observations. 
A survey method is about asking to the subject of the research specific and clear questions, in order to 
obtain an effective data. Survey method can be used in both, quantitative, as well as, qualitative studies. 
Moreover, if survey well-constructed, primary data are relatively easy to analyse, the survey method is 
faster compared to other methods of primary data collection, such as observation and experiments. 
A survey can be conducted via mail, telephone or personal interview. In this research, the data 




The Likert survey is spitted in a list of Green supply chain practices previously analysed (i.e. reverse 
logistics, supplier collaboration) as showed below. Following tables show the Likert survey of the 
research. 
 
Two main questions were asked to the subject: 
1) Is IoT technology implemented for thus GSCM practice? 
2) How positive would you define the IoT impact on this practice? 
 
Question number 1 can be answered using the following five-point Likert-type scale: 
(1 = not considering it, 2 = planning to consider it, 3 considering it currently, 4 = carrying out to some 
degree, 5 carrying it out fully) 
Question number 2 can be answered using the following five-point Likert-type scale: 
1 = not at all, 2 = a little bit, 3 = to some degree, 4 = relatively significant, 5 =significant 
 
 
Table 1: The level of IoT implementation in GSCM practice 
 
Table 2: IoT impact on GSCM practices 
In order to gather a comprehensive data of the IoT impact in GSCM, a second list follows, reporting 
disadvantages and issues. The following question was asked, to gain a quantitative grade of negative 
impact of IoT adoption:  














1. Green Design 1 2 3 4 5 
2. Green Procurement 1 2 3 4 5 
3. Green Manufacturing  1 2 3 4 5 
4. S/C Collaboration 1 2 3 4 5 
5. Reverse Logistic 1 2 3 4 5 
 How positive would you define the IoT impact on this practice? 





1. Green Design 1 2 3 4 5 
2. Green Procurement 1 2 3 4 5 
3. Green Manufacturing  1 2 3 4 5 
4. S/C Collaboration 1 2 3 4 5 




3) Has IoT created the following issue within the company? 
 
Table 3: IoT issues within the company 
 
The author conducted semi-structured interviews although all questions were prepared in advance to 
ensure the interview flowed like a conversation. 




i. When did the company start using IoT technology? 
ii. What was the major driver for the adoption of this technology along the supply chain? 
iii. How much budget / effort has been dedicated to the implementation of IoT technology? 
iv. How IoT adoption impacted the business? 
v. Does the company plan to implement this technology to improve any other aspect? 
vi. Have you experienced any problems using IoT technology?  
IoT in GSCM Practices 
vii. How IoT improved Green Design? 
viii. How IoT improved Green procurement? 
ix. How IoT improved Green manufacturing? 
x. How IoT improved supplier and customer integration? 
xi. How IoT improved Reverse Logistics? 
xii. Why do you think IoT has an overall positive/negative impact to improve GSCM practices? 
xiii. Have you experienced any problems in adopting IoT in the GSCM? 
xiv. How the company faced and resolved these challenges? 
xv. Do you think the company will intensify the use of IoT to improve GSCM practices and 
sustainability? 
  
 Has IoT created the following issue within the company? 
 





1. Security 1 2 3 4 5 
2. Privacy 1 2 3 4 5 
3. Skill gap  1 2 3 4 5 




PUBLIC HEALTHCARE (DISTRIBUTOR CENTER) 
i. Are you directly expose to IoT technology implemented by pharmaceutical companies? 
ii. When did you start to see a massive implementation of IoT technology? 
iii. How IoT technology has been implemented by pharmaceutical companies? 
iv. How wide is the use of IoT technology for reverse logistic? 
v. How wide is the use of IoT Technology for waste management? 
vi. Do you think IoT technology has a positive impact? If yes, why? 
vii. Have you experienced any problems using IoT technology? 
viii. Do you think Pharmaceutical companies could do more to improve sustainability? 
3.4.2 ACCESS AND ETHICAL ISSUES 
The significant success of the research relies on accessing valid data sources. There are distinctive 
strategies that can help to research proper data (Saunders et al., 2009). This research proposal focuses 
on survey and interview methods, following a specific data collection strategy. 
There are several ways to achieve successful survey data results. It is important to have a clear and 
narrow definition of survey objectives; it can help to gain right data results. Identification of right 
audience is as important as survey objective; it can hugely impact survey results. Furthermore, adequacy 
of question is necessary to achieve significant results in research. Although, testing survey may not see 
necessarily before the real practices, it is important to test on different platforms due to lack of 
technology. 
There are several key issues to gain access to data, such as organisation may not wish to allocate sources 
due to sensitivity of the data. In terms of ethical issues, all the participants of the survey and relative 
firm have the right to remain anonymous (Saunders et al., 2009). Therefore, the author is responsible 
to ensure the keeping safe all personal and confidential data in order to avoid breach of data protection.  
3.5 DATA ANALAYSIS 
The survey has been set out to discover which IoT solutions are used in pharmaceutical GSCM.  To be 
able to determine the positive impact on every GSCM practices. In regard of quantitative data, mean 
scores is computed from the responses given by all the respondents on the Likert Scale. The factors 
scoring higher mean value, for each objective, were assumed to be the ones with the most significant 
effect. 
An integration of quantitative and qualitative data is performed to understand the negative impact of 
IoT adoption; a general quantitative impact factor is gathered by the 3rd question, then further 
qualitative date (ad doc interview) is used to understand the effect of the negative impact on the Green 
supply chain and where along the supply chain has caused damage.  
Further qualitative data through the interview, is necessary to understand why the interviewee has 





CHAPTER FOUR: FINDINGS AND DISCUSSION 
4.1 FINDINGS 
This chapter will explore the interview findings, which are the result of the previously explored 
conceptual framework. Every finding corresponds to one or more questions answered by each 
pharmaceutical company involved in the study.  The author created two different sets of questions, one 
set is suitable for company operating in the pharmaceutical sector, the other set is to gather useful 
information from public healthcare. The author decided to involve public healthcare in the research 
because it is an essential point in the pharmaceutical supply chain. Distribution centres as public 
healthcare link directly all pharmaceutical companies to the customers. 
The first step was to create the following tables with the data collected, in order to review the validity 
and provide an overview of information that the interview provided. When the interview did not provide 
sufficient data, the company was discarded from the study, it is important to note that many positions 
within the organization have not sufficient background or knowledge of IoT technology and the full 
supply chain. Furthermore, in order to comply with data privacy requirements was given to the 
interviewee the possibility to remain anonymous. Disclosure of sensitive data is of particular concern 
in the pharmaceutical industry.  
It is important to note that not all questions were addressed during the interview, due to several reasons: 
privacy concerns, inapplicability reasons and inadequate knowledge on the topic. The following tables 
report the addressed questions for each company. 
Once the subject of the research was established, to analyse the consistency of the data acquired, a 
comparative collection of findings was undertaken by the author in order to confirm the hypothesis 
previously postulated in the research framework. 
  
 Question 
 IoT Implementation 
1 2 3 4 5 6 
Pfizer X X X X X X 
Novartis X X X X N/A X 
BIEM X X N/A X X X 










 GSCM and IoT 
7 8 9 10 11 12 13 14 15 
Pfizer X X X X X X X X X 
Novartis X X X X N/A X X N/A X 
BIEM X X X X X X X N/A X 
Table 5: GSCM and IoT Questionnaire responses 
Overview of Companies 
Pfizer is an American biopharmaceutical company that operates globally, with headquarter in New 
York city and over 96.599 employees is one of the biggest pharmaceutical company in the market. 
The company develops and produces medicines for a wide range of medical disciplines, including 
immunology, oncology, cardiology, endocrinology, and neurology. Well know products are Lipitor, 
Lyrica, Viagra, Celebrex, Xerox. Pfizer has major manufacturing facilities in Belgium, China, 
Germany, India, Ireland, Italy, Japan, Puerto Rico, Singapore, and the US. In all, it operates 63 plants 
around the world, and IoT is being used on different aspects along the supply chain. 
The author’s contact in this firm was the Supply Chain Lead Network Solutions for EMEA distribution, 
he is responsible to deliver Supply chain operations across over 20 countries.  
The person for data privacy reasons wished to remain anonymous. For simplicity, the author will refer 
to the company and not the person. The interview was conducted by means of email correspondence, 
after detailed research information at current data was shared. The author on all the questions forwarded 
to the interviewed person obtained detailed data.  
Novartis is a Swiss pharmaceutical company operating worldwide, with 129.924 employees and their 
presence on the market in 155 countries. Novartis aims to improve and extend people’s lives, using 
innovative technology and breakthrough science. This organization develop and produce transformative 
drugs and innovative treatments in various filed as oncology, respiratory, immunology, neuroscience 
and cardiovascular. Well-known medicines are Gilenya for multiple sclerosis and Gleevec cancer drug.  
The author’s contact in this firm was the clinical quality and data specialist in Novartis, he is actively 
involved in clinical trials, data analysis from manufacturing sites, and identification and resolution of 
error/ inconsistency to ensure high quality. The person for data privacy reasons wished to remain 





BIEM is a medium sized Turkish pharmaceutical company with headquarters in Ankara, is a privately 
held pharmaceutical company engaged in manufacturing, distribution and marketing of pharmaceutical 
and healthcare products. BIEM is conducting its operations in North America, Chile, CEE, Russia, 
South Africa, ASEAN, MENA and CIS countries, either through distributors or its own affiliates. The 
company develops and produces wide range of medicines including biologicals, oncology, 
haematology, ophthalmology, radiology and gynaecology. Well known medicines are Beastin, 
Biemefrin, Biemoxol, Biemib, Biemparin, Buslera, Calsipar, Caspobiem, Conjiten, Desibem, and 
Zaridinex.  
The author’s contact in this firm was the procurement and logistics manager in BIEM pharmaceuticals. 
The person for data privacy reasons wished to remain anonymous. The interview was conducted via 
phone and a transcript created. 
Public Healthcare 
The author’s contact in the public healthcare was Mrs. Adriana Panettieri, head of maternity department 
in a public hospital in Italy, the interviewee is responsible to lead the department, organize stocks and 
inventory maintenance. The interview was conducted via mail due to unavailability of the interviewee. 
Maternity department specializes in caring for women during pregnancy and childbirth and provides 
health care services for infants. The maternity units is composed of 30 employees and registered during 
2019 circa 220 birth and was responsible to cure over 150 complicated maternities cases. 
1. IoT Technology: Major Drivers and When  
This finding was the result of the following two questions: 
When did the company start using IoT technology? 
What was the major driver for the adoption of this technology along the supply chain? 
 
According to the author’s contact in Pfizer, the company is constantly looking at emerging technology 
and new possibilities to improve the supply chain. In the scope of this journey, IoT technology was 
adopted to digitize the supply chain several years ago, no precise timeline was provided.  
The main reason to implement IoT was to create a highly interconnected supply network, a full end-to-
end visibility of the supply chain, from the internal stakeholders to the customers.  
The interviewee highlighted that having an interconnected supply chain is critical in an industry where 
the product saves human life, and it is highly subjected to customer demands.  
A highly interconnected network of supply/costumer information has been pointed out to be the key 
factor to a successfully supply of medicines, which improve and save lives. 
At the same time, the company can exploit end-to-end highly orchestrated supply network to improve 





In terms of Novartis the interviewee was unsure on the start date but revealed two open collaborations 
involving IoT. The first is with Amazon Web Services (AWS) and the second one is implementing 
Artificial Intelligent (AI) with Microsoft, both of them to strengthen manufacturing and supply chain 
operations. This suggests that not only the technology was implemented in the past, but also it is the 
base to enable innovative technology as Artificial Intelligence (Novartis, 2020).  
The author’s contact justified the use of such technology and in general emerging digital technologies 
as a powerful tool to help organisations improving drug discovery and development process. This 
suggests that the key factor leading to innovative technologies was initially focused on productivity and 
business grow. Furthermore, he cited technologies that became standard for every pharmaceutical 
company to achieve competitive advantage, such as vision systems, smart package.  
 
According to, author’s contact in BIEM, a specific date or year was not indicated in terms of IoT 
application in the company, but interviewee articulated that the company started the production in 2011, 
since then adopting new technologies to support an efficient manufacturing, procurement and logistic 
activities was inevitable (BIEM, 2020). 
 
With regards to public healthcare employee Mrs. Panettieri, basics tags systems were in use far before 
2010 and new technology implementation has been in use since 2010 (Panettieri, 2019). 
2. IoT Impact on The Business  
This finding was the result of the following two questions: 
How much budget / effort has been dedicated to the implementation of IoT technology? 
How IoT adoption impacted the business?  
 
The Pfizer employee was not able to provide budget info, but he clarified that when new technology is 
brought into every organization a huge effort from the company and employees is required to resolve 
incompatibilities with older technologies. Moreover, he highlighted the additional cost required to keep 
technologies up to date. This was in accordance with Novartis opinion: innovative technologies require 
great effort, time and expense. 
However, IoT technology had a positive impact on the business in many ways, according to author’s 
contact in Pfizer logistics efficiency improved, with systems such as ‘pick by voice’; real-time visibility 
tools also enabled by mobile technology as smartphone or tablet. In particular the whole underlying 
infrastructure of data capturing, and advanced analytics gave to the business infinitive possibility of 
improvement. The responder pointed out that this technology enabled incredible monitoring and control 





With regards to Novartis, author’s contact explained to the author that nowadays is hard to find a 
business without using these technologies. It is just not pharmaceuticals but also every business uses 
those technologies to achieve daily business activities. The interviewee clearly stated that all those 
technologies give an opportunity to strengthen communication and better management system 
(Novartis, 2020). 
 
In terms of BIEM, the budget was not provided, the interviewee simply clarified that ‘implication of 
such technology cost is significantly high, and the company has not adopted fully IoT technology yet, 
for this reason it is hard to answer the insight impact- we have general positive results till now in the 
area where such technology has been used’ (BIEM, 2020). 
 
From the public healthcare point of view Mrs Panettieri explained that IoT is in use to tracing medical 
devices and the drugs this ‘…helps to manage quickly drugs and instruments, reduce lost and waste’ 
(Panettieri, 2019). 
3. IoT Technology Challenges 
This finding was the result of the following questions: 
Have you experienced any problems using IoT technology?  
Have you experienced any problems in adopting IoT in the GSCM? 
How the company faced and resolved these challenges? 
 
All of three interviewees agreed that when introducing a new technology in a well consolidate 
infrastructure, it is inevitable to face challenges and technical issues.  
The contact in Pfizer called out as main problem, the number of different systems into play, which made 
the interconnection of the supply network extremely difficult. This is usually linked to introduction of 
new technology over time and the need to keep the infrastructure up to date. 
Another key barrier that Pfizer is facing when using IoT is guarantee patient’s confidentiality, which 
also explains why it is so difficult for pharma to draw point-of-sale data for demand-sensing 
purposes. To resolve those challenges, Pfizer decided to put effort into unify the infrastructure towards 
a unique ERP system, covering financial, commercial and manufacturing sides of the business (Pfizer, 
2019). According to the contact in Pfizer the digitization and full end-to-end connectivity of the supply 
chain was possible only through a huge effort of all the members in the organization, a continued 






In the case of Novartis author’s contact made a fair point and example, the interviewee is a data analyst 
and he personally faced issues using data from sensors in the clinical trial, he clearly stated that the 
outcomes do not meet the expectation all the time (Novartis, 2020). This clearly means that the 
expectation is not always achieved when implementing innovative solutions. 
The interviewee clarified that the challenges are related to the technology, and not to a sustainable 
implementation, the author would like to point out that the interviewee did not respond when asked how 
the company faced those challenges. 
 
In terms of BIEM, the interviewee explained that the company did not experienced major problems 
using IoT, but proper training was necessary to adopt and efficiently use it. Another important aspect 
pointed out by the interviewee was that cost and expectation must be well planned by the company 
before adopting innovative technology (BIEM, 2020). 
 
According to Adriana Panettieri, simple technology implemented by pharmaceutical companies is easy 
to manage, more complicated once require additional expertise (Panettieri, 2019).  
 
This finding was enriched with quantitative data obtained from the following Likert scale questions: 
Has IoT created the following issue within the company? 
This question can be answered using the following five-point Likert-type scale: 
1 = not at all, 2 = a little bit, 3 = to some degree, 4 = relatively significant, 5 =significant 
This question was useful to the author to identify the negative impact of IoT when adopted by the 
company. The following Chart (1) shows the level of negative impact for each challenge. 
It is important to clarify that quantitative data has been analysed by the author only for the three 
pharmaceutical companies, the public healthcare has not been included. 
 
 
Chart 1: IoT challenges 










In order to analyse the results, the author utilized a mean value for each IoT issue:  
 
𝐿𝑒𝑣𝑒𝑙 𝑜𝑓 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑖𝑚𝑝𝑎𝑐𝑡 =




“Security” has an overall Level of negative impact of about 2.33, “Privacy” has a Level of negative 
impact of about 2.33, “Skill Gap” has an overall Level of negative impact of about 4, “Management” 
has a Level of negative impact of about 4. 
This quantitative data proves to the author that “Skill Gap” and “Management” are the most relevant 
concerns for organization when adopting IoT technology. This finding was also confirmed during the 
interviews.  
4. Impact on Green Design 
This finding was the result of the following question: 
How IoT improved Green Design? 
 
According to the contact in Pfizer, the company is collaborating with IBM to use IoT technology to 
develop drug and clinical therapies for Parkinson disease, IoT will enable remote measurement of health 
and quality of life in real time to speed up the clinical trials and new therapeutic decisions.  
The interviewee clarified that developing new drugs usually involves a long trial period, which is by 
nature carbon intensive: trial related travel, team commuting, distributions, energy consumption and 
coordinating centre premises. Clinical trials contribute substantially to greenhouse gas emissions, some 
consumption can be reduced using renewable energy sources, but a more effective way to reduce carbon 
emission is simply reducing trials time (Pfizer, 2019).  
 
The contact in Novartis on the other way, did not provide a specific IoT application that helps 
developing new drugs in a sustainable manner, but the interviewee expressed that “IoT in conjunction 
with AI help tracking and analysing carbon emission in real time. Furthermore, thanks to such 
technology the company is able to understand supplier performance and align them to follow best 
practices” (Novartis, 2020). 
 
With regards to BIEM, the interviewee explain that the company did not obtain innovative technology 





5. Impact on Green Procurement   
This finding was the result of the following question: 
How IoT improved Green Procurement? 
 
According to the author’s contact in Pfizer, such technology supported the company to achieve a 
sustainable procurement evaluating external vendors with real time and remote monitoring, in this way 
the organization is able to assure correct and sustainable sourcing, at the same time, this saves money, 
reduce waste and improve competitiveness. As explained by the interviewee external benchmark of 
research and manufacturing sites are conducted for evaluating sustainability and supply chain 
management operations, KPI and risk management are main indicators for a sustainable and responsible 
supplier (Pfizer, 2019) 
 
In term of Novartis, there is high collaboration between the company and suppliers in order to achieve 
sustainability. Specifically, the interviewee mentioned that ‘using smart warehouse makes easier and 
more efficient to monitoring and tracking our asset achieve sustainability, avoiding shortage or 
overload’ (Novartis, 2020). It is transparent that IoT technology is used for monitoring and tracking 
purpose and an integration of information between supplier and the company is helping to achieve 
sustainable procurement.   
 
In sequence, the contact in BIEM explained that IoT widely in use to trace and monitor the entire supply 
chain such as sensors to control temperature or identify the damage. 
The interviewee expressed that “tracing and monitoring our goods give us a competitive advantage on 
procurement and logistics, reducing costs and waste. This of course makes logistics and procurement 
operation more environmentally friendly” (BIEM, 2020).  
6. Impact on Green Manufacturing  
This finding was the result of the following question: 
How IoT improved Green manufacturing? 
 
Pfizer interviewee highlighted that IoT helps to support green manufacturing in various way in the 
company. Moreover, the implications and the benefit of the IoT was explained in detail by the responder 
“Our organization requires its facilities worldwide to quantify water use, report performance against 
reduction targets, IoT can enable data collection scope for water metrics to align more closely with 
those of the Global Reporting Initiative. IoT application helped us to understand water-related risk and 
opportunities in our operations. Sustainability of the manufacture plants are achieved also reducing 





Regarding Novartis, the interviewee expressed his knowledge “Well, environmental sustainability is a 
growing concern in many manufacturing companies including pharmaceuticals. Facilities and 
operations may require great amount of energy and water usage. Unfortunately, this situation cause to 
increase carbon footprint and waste. We use IoT to improve our conserve resources in the green 
manufacturing process such as energy and water.  We have already made significant progress toward 
reducing water, energy and waste. Also, thus improved carbon footprint. Another major area of concern 
for the organization is water quality and preventing pharmaceutical to enter into the environment, 
technologies as IoT help us monitoring, control and achieve our reduction target” (Novartis, 2020). 
 
With regards to BIEM, the interviewee pointed out that IoT has a contribution in order to achieve 
sustainability in the manufacturing activities. Those activities addressed by the responder as; energy 
efficiency, identify quality issues, maintain warehouse inventories and asset management. In addition, 
she underlined as follows: ‘Let’s say that IoT is intervening massively in our manufacturing plants’ 
(BIEM, 2020). 
7. Impact on Supplier Customer Integration 
This finding was the result of the following question: 
How IoT improved supplier and customer integration? 
This question was responded by the Pfizer interviewee “Our organization is active in more than 175 
countries and with a product line of more than 24,000 SKUs, we’re talking about a highly complex 
supply chain. IoT flexibility and the possibility to interconnect via Internet worldwide sites and different 
stakeholders is the real added value of this technology” (Pfizer, 2019). 
 
When the author asked this question to the contact in Novartis the respond was not clearly addressed 
the implications of IoT in supplier and customer integration. However, the interviewee predicted as 
follows: “I think that IoT sensor as a point of contact to sites worldwide and management software, 
which is able to join all that information are essential to have a company high view and so integrate the 
info from supplier to customer. Information is really powerful!” (Novartis, 2020). 
 
The contact in BIEM simply acknowledged this question as follow: “Regarding to, green business and 
corporate responsibility one of the most important terms is transparency. Using IoT technology gives 
us fully transparency across the value chain, which is from the source of raw materials, production line, 





8. Impact on Reverse Logistics 
This finding was the result of the following question: 
How IoT improved Reverse Logistics? 
 
According to Pfizer respond IoT technology plays a crucial role due to visibility and monitoring of the 
drugs in order to carry out reverse logistic activities.  
The interviewee mention that the success of a reverse logistics in a globalized world, depends by the 
connection and integration of the various stakeholders and customers. The end-to-end visibility of the 
drugs from the vendors to the consumer would tackle down the reverse logistic complexity (Pfizer, 
2019). 
 
In terms of Novartis, the interviewee was not sure due to his knowledge and position. 
 
As stated by BIEM, IoT technology is not directly used for reverse logistics. The interviewee pointed 
out that reverse logistic is a tough approach in pharmaceutical industry in terms of recalling drugs and 
explained as follow: “…recalling is possible from healthcare institutions and retailers, but not from 
patients. It is hard to recall from patients; they are not always aware how to safely dispose drugs. IoT 
can only intervene facilitating the process” (BIEM, 2020). 
 
Finally, Mrs. Panettieri confirmed that such technology is widely used to trace drugs. This capability in 
conjunction to proprietary management software is improving reverse logistic from the hospital to the 
pharmaceutical company. Instead, from a waste management point of view, the interviewee explained 
that ‘IoT can intervene in tracing contaminated pharmaceutical products including vaccines and 
biological products used for therapy’ (Panettieri, 2019). 
9. Overall impact on GSCM 
This finding was the result of the following question: 
Why do you think IoT has an overall positive/negative impact to improve GSCM practices? 
 
The contact in Pfizer clearly highlighted that ‘…I definitely consider IoT impact widely positive’ and 
counited to explain that “monitoring, traceability, and remote control are brought to a brand new level 
and this has a positive impact to all sustainable practices as could be waste management, energy 
reduction, drugs manufacturing and sustainable procurement” (Pfizer, 2019). 
 
Regarding to Novartis, the respond was optimistic and the author’s pointed out that IoT helps to collect 





Similarly, regarding to BIEM pharmaceuticals, the author’s contact stated that “I believe that IoT has a 
positive impact when it comes to sustainability, it is a technology that enables several aspects: tracking, 
monitoring, improving efficiency and overseeing all the supply chain operations” (BIEM, 2020). 
 
According to Panettieri, IoT technology had overall positive impact, traceability and management of 
drugs has extremely improved the sector. The interviewee clarified that challenges are inevitable when 
adopting complicated technology, but the overall impact remain extremely positive.  
 
This finding was enriched with quantitative data obtained from the following two Likert scale questions: 
1. Is IoT technology implemented for this GSCM practice? 
2. How positive would you define the IoT impact on this practice? 
 
Question number 1 can be answered using five-point Likert-type scale: 
(1 = not considering it, 2 = planning to consider it, 3 considering it currently, 4 = carrying out to some 
degree, 5 carrying it out fully) 
This question was useful to the author to obtain a high view of IoT utilization within the organizations. 
Question number 2 can be answered using the following five-point Likert-type scale: 
1 = not at all, 2 = a little bit, 3 = to some degree, 4 = relatively significant, 5 =significant 
This question was useful to the author to understand on which practice, IoT had a significant impact.  
 
The following Chart (2) shows the IoT utilization degree, for each GSCM practice considered in this 
study, it is important to clarify that quantitative data has been analysed by the author only for the three 
pharmaceutical companies, the public healthcare has not been included. 
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In order to analyse these results, the author utilized a mean value for each company:  
 
𝐷𝑒𝑔𝑟𝑒𝑒 𝑜𝑓 𝐼𝑜𝑇 𝑢𝑡𝑖𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛 =
𝑆𝑢𝑚 𝑜𝑓 𝑎𝑙𝑙 𝑙𝑖𝑘𝑒𝑟𝑡 𝑟𝑒𝑠𝑢𝑙𝑡𝑠 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝐶𝑜𝑚𝑝𝑎𝑛𝑦
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐺𝑆𝐶𝑀 𝑝𝑟𝑎𝑐𝑡𝑖𝑐𝑒𝑠
 
 
Pfizer’s Degree of IoT utilization is of about 4.4, Novartis’s Degree of IoT utilization is of about 4.2, 
BIEM’s Degree of IoT utilization is of about 3.6. This quantitative data proves to the author that larger 
pharmaceutical companies as Pfizer and Novartis have a higher degree of IoT utilization, to support 
supply chain operations. This is easily confirmed by the fact that smaller companies have lower funds 
and possibilities to invest in innovative technologies such as IoT.  
Moreover, from the above Chart (3), the author was able to identify Green Manufacturing and Supplier 
Customer Integration as the practices with higher attention and investment.  
 
In term of IoT impact on GSCM, the second question was used by the author to obtain the following 
chart, which shows the degree of IoT impact on each GSCM practice.  
From the below chart, the author extrapolate the Mean value for each practice, in order to understand 
on which practice IoT has higher impact.  
 
𝐷𝑒𝑔𝑟𝑒𝑒 𝑜𝑓 𝐼𝑜𝑇 𝑖𝑚𝑝𝑎𝑐𝑡 =




Green Design’s is of about 4. Green Procurement’s Degree of IoT impact is of about 4.67. Degree of 
IoT impact on Green Manufacturing is of about 4.34. Degree of IoT impact on Supplier customers 
integration is of about 4.67. Degree of IoT impact on Reverse Logistic is of about 3.67 
 
 
Chart 3: IoT in GSCM practices 











From the calculated data the author established that Green Procurement and Supplier Customer 
Integration were the practices with the higher IoT impact factor. Similarly, the author identified that 
IoT technology is slightly less effective on Green Design and Reverse Logistic.  
The overall impact of IoT on the totality GSCM practices is relatively significant with a Degree of IoT 
impact equal to 4.27.  
10. Future Possibilities  
This finding was the result of the following questions: 
Does the company plan to implement this technology to improve any other aspect? 
Do you think the company will intensify the use of IoT to improve GSCM practices and sustainability? 
 
The author was able to gather insight on future possible implementations of IoT from Pfizer. The contact 
in the company expressed possible involvement of such technology in the next big pharmaceutical 
development, DNA-based diagnosis and drug development, which will create personalized medicines.  
In regard of sustainability and environmental impact the interviewee expressed a strong interest to 
continue investing in this technology, due to IoT flexibility and the contribution to fight carbon 
emission, improve waste management, reduce energy consumption and reduce trial times (Pfizer, 
2019). 
 
In terms of Novartis, the interviewee did not express how the company plan to implement this 
technology in the future, but he clarified that if the technology brings value to sustainability and cost is 
justified, there is no reason to not consider IoT for future implementations.  
 
According to BIEM employee, the company is aware of IoT potential, for this reason expanding the use 
of such technology on a wider range of operations is under consideration. Furthermore, the company 
firmly support sustainability conscious that it does not only protect the environment, but it also adds 
value to the business, to achieve sustainability technology is essential (BIEM, 2020). 
 
The Table (6) below illustrates six essential matters of IoT implementation which are: when, major 
drivers, how, cost/effort, impact, problems/challenges, future possibilities for each company and public 
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Table 6: IoT technology interview findings 
 
The author was able to produce through interviews the below comprehensive Table (7), which explains 
how IoT technology actually supports GSCM practices in each company.   
The author derived for each GSCM practice common findings between the pharmaceutical companies 
and the public healthcare. These were used to create a general overview of the current scenario of IoT 
impact on GSCM practices. The author would like to clarify that data gathered were from three 





From the findings and consequent Table (7), the author was able to summarize that IoT is enabling a 
Green Design of pharmaceuticals by reducing clinical trials times and resources, monitoring 
environmental risk and enabling Artificial Intelligence, which can improve development of new drugs.  
Instead, in term of smaller company as BIEM applying IoT to develop new drugs can result in high cost 
and uncertain results. 
 
With regard of Green Procurement: IoT enables monitoring of suppliers / 3rd party companies for 
sustainable benchmark, monitoring inventory levels and tracking assets. IoT allows also the companies 
and distributor centres (public hospital) to reduce costs and waste. Finally, IoT enables supplier 
collaboration, in this way the companies effectively reduce overload and shortage. 
 
IoT intervene in several manufacturing aspects, creating a sustainable manufacturing, such technology 
allows monitoring and reduction of water and energy consumptions; in general, it can help reducing the 
company carbon emission through monitoring and control. Furthermore, monitor capabilities can 
actually help the company to identify pharmaceuticals level released in the environment from 
manufacturing sites so to undertake corrective measures.  
 
Supplier and customer integration can be achieved using IoT technology in conjunction with unified 
system such as ERP, which enables the company to cover all business sides and create an end-to-end 
supply network. Furthermore, thanks to IoT solutions information can be collected worldwide and 
integrated in real time through internet. The sustainable value of the company resides in the visibility 
and transparency across the value chain and this can be achieved using IoT along the supply chain. In 
terms of public healthcare, the integration of supplier to customer information is enabled by 
pharmaceutical companies with the use of IoT solutions. Such implementations on drugs and medical 
devices support sustainability, improving inventory management and reducing loss of medicines and 
devices.  
 
Finally, IoT is impacting Reverse Logistics indirectly, this GSCM practice is successful when a fully 
digitalized end to end supply chain is in place, and such ambitious achievement can be possible using 
IoT. This is confirmed by two companies, IoT can actually facilitate the reverse logistic process when 
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CHAPTER FIVE: CONCLUSION 
The primary goal of the research was to explore Internet of Things technology and its role in Green 
Supply Chain Management practices.  The empirical study was conducted in the pharmaceutical 
industry through examination of three pharmaceutical companies and one public healthcare centre. 
Moreover, the study focused on the practical challenges faced by pharmaceutical companies when 
adopting and implementing IoT technology. 
The author compiled a series of conclusions, based on the findings derived by primary and secondary 
sources. 
Implementation and Drivers of IoT 
Adoption of IoT technology in pharmaceutical companies has started several years ago, but the 
revolution in this sector has not concluded yet. Companies are constantly looking for innovation, and 
IoT is an essential enabler of novel solutions such as Cloud Computing and Artificial Intelligence. 
The major drivers for adopting such technology in the pharmaceutical industry were related to the 
competitive advantages that organizations aimed to achieve. The goals that pharma organisations 
pursued range from creating end-to-end visibility of the supply chain to increase productivity and 
efficiency of manufacturing or logistic activities.  For such scope, companies have implemented several 
solutions involving IoT: ERP system, ‘pick by voice’, real time visibility, AI to develop new drugs, 
smart warehousing, cold chain sensors / actuator etc. 
Barriers Against IoT 
A common finding of this research was that innovative technologies always required great effort, time 
and expense for the company. Moreover, it has been identified that when considering innovative 
technologies such as IoT, an extensive cost-benefit investigation is essential to achieve successful 
results. In some practical cases, the outcomes when using IoT technology did not meet the expectation 
all the time. This was the case of data accuracy of IoT solution in clinical trials. This clearly means that 
the company expectation is not always achieved when implementing innovative solutions. In 
conclusion, qualitative data provided additional challenges related to IoT that the author did not 
considered. Instead, the analysis of both quantitative and qualitative data confirmed management of IoT 
technology and skill gap as the most challenging matters. A common finding within all the interviews 
was that introducing a new technology in a well consolidate infrastructure inevitably creates challenges 






IoT and GSCM practices 
The primary and secondary data established that there is a positive and significant impact of IoT on 
Supplier and Customer Integration in a successful GSCM practices. IoT helps to improve visibility, 
transparency of the entire supply chain and it enables to gather data worldwide.  
Multinational organisations such as Pfizer and Novartis have a complex supply chain, flexibility and 
possibility to interconnect worldwide sites and various number of stakeholders is extremely important. 
The exploratory data proved that IoT has an overall positive impact on sustainability initiatives such as 
tracking and reducing carbon emission, resource conservation and waste management. Although, 
Reverse Logistic is a challenging subject for pharmaceutical industry, IoT improves the digitalisation 
of E2E supply chain and reduces loss and waste in the distribution. Moreover, the specific technology 
helps to monitor in real time warehouse and logistic operations e.g. monitoring and tracking sensitive 
drugs in controlled zones.   
This research also states that challenges of IoT implementation are strictly related to the technology and 
not to application of such technology in GSCM practices. A series of additional issues were discovered 
due to IoT technology, but none of them were exclusively related to GSCM practices. This suggests 
that when technological challenges are resolved, the overall negative influence of using IoT to support 
GSCM practices is reduced to minimal. 
Sustainability and Business Value 
This research started to explore the major drivers for IoT technology adoption within pharmaceutical 
companies, proving that organizations were generally looking to increase business value. 
This was useful to understand that IoT implementation was not initially driven by sustainability, but it 
is undeniable that IoT resulted to be a great supporter of GSCM practices and sustainability of the 
company. To summarise, IoT technology supports business growth, and indirectly enables sustainable 
practices.  
Based on this research, business value can be achieved when the company adopts sustainable practices 
enabled by IoT. For example, a highly orchestrated E2E supply chain network has a positive 
contribution to increase business value, but at the same time improves sustainability of the company. 
The same pattern can be recognized in every GSCM practices and IoT application. The overall positive 
impact of IoT on the GSCM practices, confirmed that exists a strong relationship between sustainability 
and business value, when using IoT. From a practical point of view, pharmaceutical companies can 





Limitation of The Research and Future Work 
This research was based on qualitative and quantitative data, which was obtained from small and large 
pharmaceutical organisations. The mixed method approach gave to the author a detailed and 
comprehensive view of IoT impact on GSCM in the pharmaceutical industry. Qualitative data was 
extremely useful to gather detailed information on IoT solutions, and how such solutions support GSCM 
in real scenarios. Instead, through quantitative data the author was able to obtain a high view prospective 
of the research topic. 
Future research can use a different methodology or can include a wider statistical sample.  It is 
important to clarify that achieve a high response rate in the pharmaceutical sector was a challenge, due 
to the technical nature of this research and the availability of interviewees to disclose organization’s 
practices. 
A possible development of this research could be obtaining only quantitative data from a more detailed 
Likert-Scale questionnaire; this would require a larger statistical sample. More specific research can be 
done separating the findings between small and big organizations and compare these results. 
Other possibilities are performing the same research in a different sector or including innovative IoT 
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